Dexcom stock trading: DXCM stock explained

This article explores Dexcom’s background, product portfolio, and the factors influencing its market valuation. It is designed for traders interested in Dexcom shares, DXCM CFD trading Dexcom with Plus500, along with essential risk management techniques, and exit strategies.

What is Dexcom?

Dexcom, Inc. (NASDAQ: DXCM) is a San Diego-based medical technology company and the global leader in continuous glucose monitoring (CGM), wearable devices that track blood sugar levels in real time, 24 hours a day, without the need for finger pricks.

Founded in 1999 and publicly listed on the NASDAQ exchange, Dexcom serves millions of people living with diabetes worldwide. Its products are used by patients, caregivers, and healthcare providers to manage Type 1 and Type 2 diabetes more accurately and more conveniently than traditional methods.

What does Dexcom make?

At the heart of Dexcom's business is the Dexcom G7, a small wearable sensor worn on the upper arm or abdomen that continuously measures glucose levels through the skin. It sends real-time readings every five minutes directly to a smartphone app, smartwatch, or compatible insulin pump, no blood draws required.

In April 2025, Dexcom received FDA clearance for its next-generation upgrade: the Dexcom G7 15-Day, the longest-lasting CGM sensor on the market and the most accurate, with an overall MARD (Mean Absolute Relative Difference) of 8.0%. Compared to the standard G7's 10-day wear, the 15 Day version reduces the frequency of sensor changes, lowering cost and inconvenience for patients.

Why does accuracy matter for investors?

A lower MARD score means readings are closer to actual blood glucose values, which directly determines whether a product remains the clinical gold standard, and therefore, whether hospitals, insurers, and patients keep choosing Dexcom over competitors.

Automated Insulin Delivery (AID) partnerships

One of Dexcom's most powerful competitive advantages is its ecosystem of integrations with leading insulin pump companies. Rather than operating in isolation, the G7 sensor acts as the "brain," feeding glucose data to automated insulin delivery (AID) systems, also known as the "artificial pancreas."

Beyond diabetes: the CGM expansion opportunity

Dexcom has been expanding CGM use beyond traditional insulin-dependent patients. Its CONNECT study highlighted significant benefits of the G7 for Type 2 diabetes patients not on insulin, a market segment far larger than Type 1, representing a potential step-change in the company's addressable market.

What influences the Dexcom stock?

Like most healthcare technology stocks, DXCM stock price responds to a distinct set of catalysts:

• Product news & FDA approvals: Clearance events (like the G7 15 Day event in April 2025) have historically caused significant short-term price reactions, both positive and negative.

• Quarterly earnings & guidance: Dexcom's July 2024 earnings triggered a dramatic ~40% single-day drop after management cut its annual revenue forecast, citing sales force restructuring. By contrast, FY2025 results showed a recovery: 16% revenue growth and net income up 45% year-over-year, demonstrating how quickly sentiment can reverse.

• Competitive pressure from Abbott: Abbott's FreeStyle Libre series is Dexcom's primary rival, competing on price and simplicity. Abbott has historically captured more of the Type 2 market at a lower price point, putting pressure on Dexcom's market share in certain geographies.

• GLP-1 drug adoption: The rise of weight-loss and diabetes drugs like Ozempic and Wegovy (GLP-1 agonists) creates a debated dynamic: The net effect remains a watched variable.

• Insurance and reimbursement policies: Coverage decisions by insurers and government healthcare programs directly determine patient access and, therefore, Dexcom's revenue trajectory.

Characteristics of CFD trading

Contracts for Difference (CFDs) are derivative products that allow traders to speculate on the price movements of financial instruments without owning the underlying asset. CFDs can be used to trade rising and falling markets by taking long (buy) or short (sell) positions across a wide range of asset classes, including shares, indices, forex, commodities, cryptocurrencies, ETFs, and options (availability varies by provider and jurisdiction). CFD trading is typically leveraged, meaning traders can gain larger market exposure with a smaller initial deposit (margin). While leverage can amplify potential returns, it also increases the risk of losses, which can exceed the initial margin if appropriate risk management measures are not used. CFD positions are generally suited to short- and medium-term trading strategies, and costs such as spreads, overnight financing charges, and other applicable fees should be considered before trading.

Sign Up

Understanding Dexcom stock risks

• Competition: Abbott's FreeStyle Libre remains a formidable rival with a lower price point and strong market share, particularly in Europe and the Type 2 segment. New entrants and Medtronic's pipeline also add competitive pressure.
• Execution risk: Dexcom's 2024 earnings shock demonstrated how quickly management missteps, in that case, a poorly executed U.S. sales force restructuring, can erase years of goodwill with investors. Execution of its commercial strategy remains a key watch item.
• Regulatory risk: CGM devices operate under strict FDA oversight. In 2025, the FDA issued a Class I recall for certain Dexcom G7 apps due to a software design defect preventing users from receiving alerts about unexpected sensor failures. Regulatory setbacks can weigh on the stock.
• GLP-1 dependency uncertainty: If GLP-1 reimbursement terms shift or clinical guidance changes, the currently positive correlation between GLP-1 adoption and CGM usage could reverse.